NMPA Approved 2023 · China Only
Fucaso® (equecabtagene autoleucel): Clinical Profile & Patient Journey Guide
For general information on how CAR‑T therapy works, visit our CAR‑T Cell Therapy Hub. For the BCMA target specifically, see BCMA CAR‑T.
Product Intelligence
1. Product Overview
🌏 China's First BCMA-Targeted CAR-T — Expanding Myeloma Access
- Fucaso (Equecabtagene autoleucel) is the first BCMA-targeted CAR-T therapy approved in China (NMPA, June 2023).
- It is the second BCMA CAR-T approved globally (after Abecma and before Carvykti in some regions), but the first in China.
- It is significantly more affordable than Western BCMA CAR-T products ($180,000-$220,000 vs $410,000-$465,000).
- This approval represents a major advancement for multiple myeloma patients in China and the broader Asian region.
| Attribute | Details |
|---|---|
| Brand Name | Fucaso® |
| Generic Name | equecabtagene autoleucel (eque‑cel) |
| Manufacturer | IASO Biopharmaceuticals (Nanjing, China) |
| Target Antigen | BCMA (B‑cell Maturation Antigen) |
| CAR Construct | Fully human BCMA‑targeting scFv + 4‑1BB costimulatory domain + CD3ζ signaling |
| Unique Feature | First BCMA CAR‑T approved in China — NMPA approval June 2023 |
| NMPA Approval | June 2023 (r/r MM after ≥3 prior lines) |
| FDA / EMA Approval | Not approved |
| Administration | Single intravenous infusion (autologous CAR‑T cells) |
| Manufacturing | Patient's own T‑cells collected via leukapheresis, genetically modified ex vivo using lentiviral vector, expanded, and reinfused |
Fucaso (Equecabtagene autoleucel) is the first BCMA-targeted CAR-T therapy approved in China, representing a significant milestone for multiple myeloma treatment in Asia. It uses a fully human scFv targeting BCMA with a 4‑1BB costimulatory domain, similar to Abecma and Carvykti.
Science
2. Mechanism of Action
Fucaso is an autologous BCMA‑directed CAR‑T cell therapy:
- T‑Cell Collection: Patient's own T‑cells are collected via leukapheresis.
- Genetic Modification: T‑cells are transduced with a lentiviral vector encoding a CAR that recognizes BCMA.
- CAR Structure:
- Targeting domain: Fully human single‑chain variable fragment (scFv) targeting BCMA
- Costimulatory domain: 4‑1BB (same as Abecma, Carvykti), which promotes T‑cell persistence and reduces exhaustion
- Signaling domain: CD3ζ, which activates T‑cell cytotoxic function
- Unique Feature: Fully human scFv may reduce immunogenicity (lower risk of anti‑drug antibodies) compared to humanized constructs.
- Expansion: Modified cells are expanded ex vivo to achieve therapeutic doses.
- Reinfusion: Patient receives lymphodepleting chemotherapy (fludarabine/cyclophosphamide), followed by single infusion of CAR‑T cells.
- Mechanism: CAR‑T cells bind BCMA on plasma cells (normal and malignant), activate cytotoxic response, and persist long‑term due to 4‑1BB signaling.
Key Distinction from CD19 CAR‑T Products:
- BCMA target is specific to plasma cells (not B‑cells).
- Fucaso is NOT approved for B‑cell malignancies (leukemia, lymphoma).
- BCMA is expressed on malignant plasma cells in >90% of multiple myeloma cases.
- On‑target, off‑tumor effect: BCMA is also expressed on normal plasma cells, leading to expected B‑cell aplasia and hypogammaglobulinemia.
Indications
3. Approved Indications
NMPA Approval — June 2023
- Adult patients with relapsed or refractory multiple myeloma who have received ≥3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent
- NMPA label: "For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent"
Clinical Trial Evidence
- Approval was based on a pivotal Phase I/II clinical trial conducted in China (equecabtagene autoleucel in patients with r/r multiple myeloma)
- Demonstrated high overall response rates with durable complete responses
- Safety profile consistent with other 4‑1BB BCMA CAR‑T products
- Fully human scFv may contribute to favorable safety profile
Important Clarification:
- Fucaso is NOT approved by FDA or EMA — currently only available in China.
- It is NOT approved for B‑cell malignancies (leukemia, lymphoma).
- Always verify specific indications with the most current prescribing information.
Evidence
4. Clinical Evidence Summary
Pivotal Phase I/II Trial (China)
- Multicenter, open‑label, single‑arm study
- Adult patients with r/r multiple myeloma after ≥3 prior lines
- Included patients who had received PI, IMiD, and anti‑CD38 antibodies
- Demonstrated high overall response rates (ORR) with durable complete responses
- Fully human scFv showed low immunogenicity
- Safety profile consistent with other 4‑1BB BCMA CAR‑T products
- Led to NMPA approval in June 2023
- Single‑arm study without control group
Key Observations
- High response rates in Chinese patient population
- Manufacturing success rate >95%
- Favorable CRS profile (lower rates of severe CRS compared to some Western products)
- Long‑term follow‑up data continue to be collected
Key Considerations:
- The pivotal trial was a single‑arm study (no control group).
- Patient populations were highly selected (good performance status, adequate organ function).
- Results may not generalize to all patients in routine clinical practice.
- Long‑term safety and efficacy data continue to be collected through post‑marketing studies.
Safety
5. Safety Profile
Fucaso carries significant safety risks that require careful patient selection and monitoring. The following are based on NMPA prescribing information and clinical trial data:
⚠️ BOXED WARNINGS (NMPA)
Cytokine Release Syndrome (CRS):
- Occurs in majority of patients (typically within first 1‑10 days post‑infusion)
- 4‑1BB construct and fully human scFv may be associated with lower severity compared to some constructs
- Symptoms: fever, hypotension, hypoxia, organ dysfunction
- Severe (Grade 3‑4) CRS occurs in approximately 5‑10% of patients
- Management: tocilizumab (IL‑6 receptor antagonist), corticosteroids, supportive care
Neurologic Toxicities (ICANS):
- Immune effector cell‑associated neurotoxicity syndrome (ICANS)
- Symptoms: encephalopathy, aphasia, seizures, cerebral edema
- Typically occurs within first 8 days post‑infusion
- Severe (Grade 3‑4) ICANS occurs in approximately 10‑15% of patients
- Management: corticosteroids, supportive care
Other Serious Adverse Reactions:
- Prolonged cytopenias: Neutropenia, thrombocytopenia, anemia (may persist for weeks to months)
- Infections: Increased risk due to B‑cell aplasia and hypogammaglobulinemia; prophylactic antimicrobials and immunoglobulin replacement may be required
- Hemophagocytic lymphohistiocytosis (HLH) / Macrophage activation syndrome (MAS): Rare but potentially fatal
- Hypogammaglobulinemia: Expected on‑target effect due to BCMA expression on normal plasma cells; requires monitoring and immunoglobulin replacement
Long‑Term Monitoring:
- Patients must be monitored long‑term for persistent cytopenias, infections, and secondary malignancies
- Annual follow‑up recommended for at least 15 years per NMPA requirement
Regulatory
6. Regulatory Status
| Region | Regulatory Authority | Approval Status | Approval Date |
|---|---|---|---|
| China | NMPA | Approved (r/r MM ≥3 prior lines) | June 2023 |
| United States | FDA | Not approved | — |
| European Union | EMA | Not approved | — |
| United Kingdom | MHRA | Not approved | — |
| Japan | PMDA | Not approved | — |
(Regulatory status may change. Always verify current approval status with regional regulatory authorities.)
Cost & Access
7. Cost & Access Information
Pricing (Approximate, Out‑of‑Pocket for International Patients)
| Country | Approximate Cost (USD) | Notes |
|---|---|---|
| China | $180,000 – $220,000 | Significantly lower than Western products; does not include hospitalization, supportive care, or management of complications |
| Other Regions | Not available | Only approved in China; not available internationally |
Significant Cost Advantage:
- Fucaso is priced substantially lower than FDA/EMA approved BCMA CAR‑T products ($180,000‑$220,000 vs $410,000‑$465,000).
- This makes BCMA CAR‑T therapy more accessible to multiple myeloma patients in China and the broader Asian region.
- However, international patients must consider travel, accommodation, and extended stay costs.
Total Treatment Cost Considerations
- The drug acquisition cost is only one component.
- Additional costs include:
- Leukapheresis and cell collection
- Lymphodepleting chemotherapy
- Hospitalization (typically 2‑4 weeks minimum)
- Management of CRS/ICANS (tocilizumab, corticosteroids, ICU care if needed)
- Long‑term follow‑up and monitoring
- Immunoglobulin replacement therapy
- Total treatment episode cost can exceed $280,000‑$380,000 in China when all components are included.
International Access
- Fucaso is only available in China — not approved in the US, EU, UK, or Japan.
- International patients seeking Fucaso must travel to certified treatment centers in China.
- Our platform can facilitate introductions to certified treatment centers in China, but we cannot guarantee access or coverage.
Compare
8. Comparison with Other BCMA CAR‑T Products
| Feature | Fucaso (eque‑cel) | Abecma (ide‑cel) | Carvykti (cilta‑cel) |
|---|---|---|---|
| Manufacturer | IASO Biopharmaceuticals | BMS / bluebird bio | Janssen / Legend Biotech |
| Target | BCMA | BCMA | BCMA |
| scFv Type | Fully human | Humanized | Humanized |
| Costimulatory Domain | 4‑1BB | 4‑1BB | 4‑1BB |
| Approved Region | China (NMPA) | FDA, EMA | FDA, EMA |
| Approved Indication | r/r MM (≥3 prior lines) | r/r MM (≥2‑4 prior lines) | r/r MM (≥1‑4 prior lines) |
| Approximate Cost (US) | $180,000‑$220,000 | $410,000‑$430,000 | $465,000 |
| CRS (Grade 3‑4) | ~5‑10% | ~8‑10% | ~4‑5% |
| ICANS (Grade 3‑4) | ~10‑15% | ~15‑20% | ~15‑20% |
| Manufacturing Time | 3‑4 weeks | 3‑4 weeks | 3‑4 weeks |
| Approval Year | 2023 (China) | 2021 (FDA), 2023 (expanded) | 2022 (FDA), 2024 (expanded) |
These are general pharmacological differences. Individual patient responses vary. Treatment selection should be based on specific clinical circumstances, disease characteristics, and physician recommendation.
Questions
Frequently Asked Questions
Common questions about Fucaso and BCMA CAR‑T therapy in China.
What is Fucaso and why is it significant? ▾
Fucaso (equecabtagene autoleucel) is the first BCMA‑targeted CAR‑T therapy approved in China (NMPA, June 2023). It significantly expanded access to BCMA CAR‑T therapy for multiple myeloma patients in China and is priced substantially lower than Western products.
Is Fucaso approved by FDA or EMA? ▾
No. Fucaso is currently only approved by the NMPA (China). It is NOT approved by FDA, EMA, MHRA, or PMDA.
What makes Fucaso different from other BCMA CAR‑T products? ▾
Fucaso uses a fully human scFv targeting BCMA, which may reduce immunogenicity (lower risk of anti‑drug antibodies). It also has a favorable CRS profile and is significantly more affordable ($180,000‑$220,000 vs $410,000‑$465,000 for Western products).
How much does Fucaso cost compared to other BCMA CAR‑T products? ▾
Fucaso is priced at $180,000‑$220,000 — significantly lower than Abecma ($410,000‑$430,000) and Carvykti ($465,000). However, international patients must factor in travel, accommodation, and extended stay costs in China.
Can I travel to China for Fucaso treatment? ▾
Yes, but Fucaso is only available at certified treatment centers in China. International patients must coordinate with the center for medical records transfer, pre‑treatment evaluation, and the manufacturing process. Plan for at least 2‑3 months away from home including recovery. Our platform can facilitate introductions to certified centers in China.
Medical Disclaimer: CancerCareE is an independent platform for patient information and introduction. It is not a healthcare provider. All medical decisions are made by licensed physicians.
Legal Framework •
Financial Transparency •
CAR‑T Hub